LIFILEUCEL

UNII:	R0835E18NH
Formula:
Preferred Substance Name:	LIFILEUCEL
GSRS Full Record:	R0835E18NH i

2306267-74-1
AMTAGVI
AN AUTOLOGOUS CD4+ AND CD8+ TUMOR INFILTRATING LYMPHOCYTE, DERIVED FROM ISOLATED METASTATIC MELANOMA CULTURED IN THE PRESENCE OF FEEDER CELLS (IRRADIATED ALLOGENEIC MONONUCLEAR CELLS FROM HEALTHY DONORS), AND HUMAN RECOMBINANT INTERLEUKIN 2/MUROMONAB-CD3 FOR TREATMENT OF METASTATIC MELANOMA
AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES (TIL) DERIVED FROM THE PATIENT'S OWN TUMOR.
HUMAN CULTURE EXPANDED ACTIVATED AUTOLOGOUS T CELLS FOR CELL-BASED IMMUNOTHERAPY. THE CELL SUBSTANCE IS A HETEROGENEOUS MIXTURE CONSISTING OF CD4+ AND CD8+ TUMOR-INFILTRATING LYMPHOCYTES (TIL), DERIVED FROM ISOLATED TUMOR BIOPSY OF PATIENTS WITH MELANOMA OR CERVICAL CARCINOMA, AND CULTURED IN THE PRESENCE OF FEEDER CELLS (IRRADIATED ALLOGENEIC MONONUCLEAR CELLS FROM HEALTHY DONORS) AND HUMAN RECOMBINANT INTERLEUKIN 2 (IL-2)/OKT3 ANTI-CD3 ANTIBODY (MUROMONAB-CD3 (59) (29) FOR T-CELL ACTIVATION
LIFILEUCEL [INN]
LIFILEUCEL [USAN]
LIFILEUCEL [WHO-DD]
LN 145 [WHO-DD]
LN-144
LN-145
TUMOR INFILTRATING LYMPHOCYTES, AUTOLOGOUS (FROM MELANOMA TUMORS)

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

LIFILEUCEL

Synonyms and Mappings

Resources